Lyell Immunopharma Inc
For the period ended Mar 31, 2024. Filed May 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 6, 2024
LYEL$15.42+3.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except per share amounts)
| March 31,2024 | December 31,2023 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $125,650 | $145,647 |
| Marketable securities | 400,650 | 400,576 |
| Prepaid expenses and other current assets | 7,865 | 8,463 |
| Total current assets | 534,165 | 554,686 |
| Restricted cash | 286 | 284 |
| Marketable securities, non-current | — | 16,506 |
| Other investments | 19,000 | 32,001 |
| Property and equipment, net | 97,836 | 102,654 |
| Operating lease right-of-use assets | 38,695 | 39,663 |
| Other non-current assets | 4,238 | 4,235 |
| Total assets | $694,220 | $750,029 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $4,895 | $4,817 |
| Accrued liabilities and other current liabilities | 24,914 | 28,126 |
| Success payment liabilities | 2,544 | 1,576 |
| Total current liabilities | 32,353 | 34,519 |
| Operating lease liabilities, non-current | 55,159 | 56,894 |
| Other non-current liabilities | 3,551 | 3,664 |
| Total liabilities | 91,063 | 95,077 |
| Commitments and contingencies (Note 11) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 10,000 shares authorized at March 31, 2024 and December 31, 2023; no shares issued and outstanding at March 31, 2024 and December 31, 2023 | — | — |
| Common stock, $0.0001 par value; 500,000 shares authorized at March 31, 2024 and December 31, 2023; 254,927 and 253,958 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 25 | 25 |
| Additional paid-in capital | 1,666,315 | 1,657,133 |
| Accumulated other comprehensive loss | (404) | (94) |
| Accumulated deficit | (1,062,779) | (1,002,112) |
| Total stockholders’ equity | 603,157 | 654,952 |
| Total liabilities and stockholders’ equity | $694,220 | $750,029 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.